Proteomics technologies for the study of autoimmune disease

Robinson, William H.; Steinman, Lawrence; Utz, Paul J.

doi:10.1002/art.10129

Cited by 68 publications

(34 citation statements)

References 69 publications

(73 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Myelin arrays and the associated methods used in this work were previously described in detail (13,24,25). Ordered Ag arrays were produced using a robotic microarrayer to attach myelin and control peptides and proteins to ArrayIt SuperEpoxy microscope slides (TeleChem International).…”

Section: Array Data Analysismentioning

confidence: 99%

A Suppressive Oligodeoxynucleotide Enhances the Efficacy of Myelin Cocktail/IL-4-Tolerizing DNA Vaccination and Treats Autoimmune Disease

Fontoura

Platten

et al. 2005

The Journal of Immunology

Self Cite

View full text Add to dashboard Cite

Targeting pathogenic T cells with Ag-specific tolerizing DNA vaccines encoding autoantigens is a powerful and feasible therapeutic strategy for Th1-mediated autoimmune diseases. However, plasmid DNA contains abundant unmethylated CpG motifs, which induce a strong Th1 immune response. We describe here a novel approach to counteract this undesired side effect of plasmid DNA used for vaccination in Th1-mediated autoimmune diseases. In chronic relapsing experimental autoimmune encephalomyelitis (EAE), combining a myelin cocktail plus IL-4-tolerizing DNA vaccine with a suppressive GpG oligodeoxynucleotide (GpG-ODN) induced a shift of the autoreactive T cell response toward a protective Th2 cytokine pattern. Myelin microarrays demonstrate that tolerizing DNA vaccination plus GpG-ODN further decreased anti-myelin autoantibody epitope spreading and shifted the autoreactive B cell response to a protective IgG1 isotype. Moreover, the addition of GpG-ODN to tolerizing DNA vaccination therapy effectively reduced overall mean disease severity in both the chronic relapsing EAE and chronic progressive EAE mouse models. In conclusion, suppressive GpG-ODN effectively counteracted the undesired CpG-induced inflammatory effect of a tolerizing DNA vaccine in a Th1-mediated autoimmune disease by skewing both the autoaggressive T cell and B cell responses toward a protective Th2 phenotype. These results demonstrate that suppressive GpG-ODN is a simple and highly effective novel therapeutic adjuvant that will boost the efficacy of Ag-specific tolerizing DNA vaccines used for treating Th1-mediated autoimmune diseases.

show abstract

Section: Array Data Analysismentioning

confidence: 99%

A Suppressive Oligodeoxynucleotide Enhances the Efficacy of Myelin Cocktail/IL-4-Tolerizing DNA Vaccination and Treats Autoimmune Disease

Fontoura

Platten

et al. 2005

The Journal of Immunology

Self Cite

View full text Add to dashboard Cite

show abstract

“…Similar to genomics, ribonomics, and metabolomics, proteomics allows parallel analyses to be conducted on hundreds of different antigens/antibodies in minimal quantities of biologic fluids, with the aim of identifying the proteins or polypeptides encoded by messenger RNA transcripts, which are up-or down-regulated in association with a particular disease (51).…”

Section: Detection Of Multiple Autoantibodiesmentioning

confidence: 99%

Are we at a stage to predict autoimmune rheumatic diseases?

Bizzaro¹,

Tozzoli²,

Shoenfeld³

2007

Arthritis & Rheumatism

View full text Add to dashboard Cite

“…In recent years, interesting and promising proteomic approaches have been developed to define autoantibody responses in autoimmune diseases [82]. Extending the technique previously developed by Joos et al [83], Mac-Beath and Schreiber [84], Haab et al [85], Robinson et al [29] established protein microarrays consisting of derivatized microscope slides on which putative peptides and autoantigens derived from target tissues are deposited.…”

Section: Profiling Of the Autoantibody Response In Multiple Sclerosismentioning

confidence: 99%

Proteomic strategies in multiple sclerosis and its animal models

Elkabes

2007

Proteomics Clinical Apps

View full text Add to dashboard Cite

The early and precise diagnosis, the prognosis, and the clinical management of multiple sclerosis, remain a considerable challenge. In recent years, the development of novel and powerful proteomic techniques prompted the use of these approaches for the search of unique biomarkers in the cerebrospinal fluid of multiple sclerosis patients. A few studies have also utilized proteomics to delineate the profile of differentially expressed proteins in animal models of the human disease in order to gain global insights into affected pathways. The identification of differentially expressed proteins may be an initial step in the discovery of novel targets and mechanisms that play critical roles in the pathology of multiple sclerosis. Based on these findings, future investigations may elucidate the events leading to demyelination, axonal damage, and neurodegeneration, providing better insights into mechanisms governing the onset and progression of the disease. Although these proteomic studies provide valuable information, they are also faced with a number of challenges. The present review discusses some of the strengths and limitations of proteomic investigations as applied to multiple sclerosis.

show abstract

Proteomics technologies for the study of autoimmune disease

Cited by 68 publications

References 69 publications

A Suppressive Oligodeoxynucleotide Enhances the Efficacy of Myelin Cocktail/IL-4-Tolerizing DNA Vaccination and Treats Autoimmune Disease

A Suppressive Oligodeoxynucleotide Enhances the Efficacy of Myelin Cocktail/IL-4-Tolerizing DNA Vaccination and Treats Autoimmune Disease

Are we at a stage to predict autoimmune rheumatic diseases?

Proteomic strategies in multiple sclerosis and its animal models

Contact Info

Product

Resources

About